Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

NCT02970942 · Completed

Last updated 2026-05-28

This clinical trial is testing three different daily doses of a medication called semaglutide, given as an injection under the skin, compared to a placebo, in adults with non-alcoholic steatohepatitis (NASH) to see if it helps improve liver health after 72 weeks.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 320 people

Who can join Ages 18–75 · all sexes

Timeline Started 2016-11 · est. completion 2020-03

Where 158 sites · Australia, Austria, Belgium, Bulgaria, Canada, Denmark, Finland, France, Greece, Japan, Netherlands, Puerto Rico, Russia, Spain, Sweden, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT02970942 ↗

Description as written by the study sponsor.

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis

Treatments tested

Semaglutide Drug

Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
Placebo Drug

Once daily administration subcutaneously ( s.c., under the skin)

Main thing measured	Percentage of Participants With Non- Alcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 72 Weeks (Yes/No)
Sponsor	Novo Nordisk A/S
Conditions studied	Hepatobiliary Disorders, Non-alcoholic Steatohepatitis
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02970942 ↗